SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs lead product, DefenCath, could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and revenue. Traders dispute how definitive DaVitas preliminary outlook is, pointing to CMSs published rate estimates and arguing that greater use could offset lower reimbursement.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention ahead of its upcoming earnings, with traders debating whether growth will support the stock after a volatile pullback. Bullish traders expect a strong report, while others cite valuation and unverified concerns about security issues in third-party apps as reasons for caution.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal Q4 results are driving discussion: a modest earnings beat and resilient payment activity are tempered by a slower-growth outlook, prompting a sell-the-news reaction. Bulls point to durable consumer spending and cross-border activity, while skeptics argue the results and guidance fall short of expectations.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS, prompting debate over how much competition could affect its sales. Traders are split: some see the rival as a serious threat, while others emphasize Precigens full approval and commercial head start, alongside questions about Inovios accelerated-approval requirements and ability to launch.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq and tech-sector selloff has driven attention to TQQQ, with traders citing worries about AI spending and earnings alongside inflation, interest-rate, and geopolitical risks. The community is split between buying the steep dip for a possible rebound and warning that further losses may follow.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a listed treasury proxy for Hyperliquids HYPE token, with traders linking its swings to HYPEs rally and the broader ecosystems growth. Bulls see room for a catch-up move or short squeeze, while bears point to share issuance and dilution as reasons PURR has lagged the token.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys strong quarterly results and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling a rally to record highs. Bulls point to continued growth in its obesity-drug franchise, while skeptics highlight the trimmed profit outlook, rich valuation, and weaker-than-expected Foundayo sales.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a 52-week high as traders anticipate its Q3 results and continued BRIUMVI growth; some attribute the move to earnings expectations, while others speculate about a buyout or short covering. No acquisition has been confirmed, and the earnings date remains unconfirmed.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results, led by strong parks performance and improving streaming profitability, have renewed optimism about Disneys turnaround under new leadership. Traders are debating whether those business trends can lift the stock after its muted, range-bound performance.

Internet Computer (ICP) is a cryptocurrency launched in 2021. Internet Computer has a current supply of 558,194,898.12638538. The last known price of Internet Computer is 2.5370221 USD and is up 5.18 over the last 24 hours. It is currently trading on 447 active market(s) with $63,762,762.22 traded over the last 24 hours. More information can be found at https://internetcomputer.org/.

Internet Computer

Discussion centers on ICPs sovereign-cloud and AI infrastructure ambitions, including posts about a Pakistan national chat app beta and potential government adoption. Bulls view these as signs of real-world utility, while skeptics point to weak adoption, token-supply concerns and prolonged underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?

Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.

Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note

Doximity (DOCS) closed the most recent trading day at $33.63, moving 1.81% from the previous trading session.

What's Next for Doximity, Inc. Shareholders After 23% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

What's Next for Doximity, Inc. Shareholders After 23% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline What's Next for Doximity, Inc. Shareholders After 23% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class...

DOCS DEADLINE: SueWallSt Reminds Doximity, Inc. Investors of Upcoming Securities Class Action Deadline

DOCS DEADLINE: SueWallSt Reminds Doximity, Inc. Investors of Upcoming Securities Class Action Deadline DOCS DEADLINE: SueWallSt Reminds Doximity, Inc. Investors of Upcoming Securities Class Action DeadlinePR NewswireNEW YORK, Oct. 29, 2026 Doximity's CEO and former CFO are named as alleged...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Doximity, Inc. of Class Action Lawsuit and Upcoming Deadlines - DOCS

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Doximity, Inc. of Class Action Lawsuit and Upcoming Deadlines - DOCS INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Doximity, Inc. of Class Action Lawsuit and Upcoming...

Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has launched DoseCheck, a free additional safety layer in Doximity Ask that instantly checks every AI-generated medication dosing claim against a structured drug database to reduce treatment errors and...

DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & KorsinskyPR NewswireNEW YORK, Oct. 28, 2026 Wall Street...

What Does Doximity, Inc.'s 23% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Does Doximity, Inc.'s 23% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Does Doximity, Inc.'s 23% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action...

What Should Doximity, Inc. Investors Know After 23% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Should Doximity, Inc. Investors Know After 23% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Should Doximity, Inc. Investors Know After 23% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action...

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 26, 2026 NEW YORK, Oct. 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds...

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity Inc - Ordinary Shares - Class A

DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>CEO Jeff Tangney attributed Doximity’s performance over Anthropic to proprietary medical data and physician oversight.</li><li>Canaccord and BMO Capital raised their price targets on Doximity, citing growing demand for the company's AI products.</li><li>Canaccord forecast that AI revenue would become a meaningful growth driver in the third quarter.</li></ul>Shares of Doximity (DOCS) surged as much as over 200% in pre-market trade on Friday before paring most of the gains despite an earnings miss after CEO Jeff Tangney touted the company’s growing artificial intelligence capabilities and said that its clinical AI outperformed Anthropic's latest model in physician-focused testing.&nbsp;During the earnings call, Chief Executive Jeff Tangney said Doximity's clinical AI recorded a 4.8% error rate, compared with 13.6% for what he called Anthropic's “best model”, Fable 5.Canaccord also raised its price target on DOCS stock to $36 from $30 and kept a ‘Buy’ rating on the shares, citing growing demand for Doximity's AI products, especially from pharmaceutical companies. Meanwhile, BMO Capital raised its price target to $30 from $20 and kept a ‘Market Perform’ rating on the shares.&nbsp;DOCS stock more than tripled at one point in pre-market trading before the rally cooled to about 100%, putting the shares on track to hit a six-month high. The stock was among the top trending tickers on Stocktwits, and on track to hit highs not seen since January.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/DOCS_2026_08_07_07_30_17_c573acda34.png" alt="DOCS_2026-08-07_07-30-17.png" width="2643" height="1588"><figcaption>DOCS stock’s performance year-to-date. | Source: TradingView</figcaption></figure>If the gains hold above 40%, the rally would mark the biggest single-day gain in the stock's history, surpassing the previous record of 38.74% set in August 2024.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260807_072949232_ff7ee6d5f9.png" alt="koyfin_20260807_072949232.png" width="2400" height="1240"><figcaption>DOCS stock’s historical single-day gains. | Source: Koyfin</figcaption></figure><h2 class="st-heading-2">Doximity Says Its AI Outperformed Anthropic</h2>Tangney said Doximity’s performance advantage over Anthropic stemmed from two key differentiators. The first is a built-in, expert-verified drug reference system designed to improve dosing accuracy and drug interaction checks. The other is a network of more than 12,000 physician "PeerCheck" editors who continuously review and refine the platform's AI-generated responses."We're proving you can still post best-in-class software margins while investing heavily in clinical AI," Tangney said. "We're leaning in because we see a once-in-a-generation opportunity to build the new AI age of medicine."He added that AI represents "the next chapter" in Doximity's growth strategy, building on its position as a digital platform for physicians.<h2 class="st-heading-2">Canaccord Sees AI Becoming A Major Growth Driver</h2>The brokerage said AI revenue has yet to materially contribute to Doximity's financial results but is already generating meaningful customer interest.&nbsp;Analysts pointed to growing demand from pharmaceutical companies for Doximity's AI tools, particularly search marketing capabilities within its "Ask" platform, which they said is driving engagement with clients.Canaccord expects meaningful AI monetization to begin in the third quarter, with the segment becoming an increasingly important contributor to the company's long-term growth.BMO Capital echoed the view, stating AI Search traction and increased AI utilization support long-term monetization. However, the firm added that near-term margin pressure from higher compute costs may weigh on the balance sheet.<h2 class="st-heading-2">How Is Retail Feeling About DOCS Stock?</h2>On Stocktwits, retail sentiment around DOCS stock improved to ‘extremely bullish’ from ‘bullish’ over the past day, while chatter rose to ‘extremely high’ from ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_08_07_070424_1_03bfe0a28d.png" alt="Screenshot 2026-08-07 070424 (1).png" width="1274" height="684"><figcaption>DOCS stock retail sentiment on August 7 as of 7:45 a.m. ET | Source: Stocktwits</figcaption></figure>Many retail traders on the platform warned that the rally in DOCS might be a short squeeze in the making.<stembedurl>https://www.stocktwits.com/Iorgi/message/661226224</stembedurl><stembedurl>https://www.stocktwits.com/AsymmetricUpsideEnjoyer/message/661231790</stembedurl>Not accounting for the pre-market rally, DOCS stock has dropped more than 50% this year and nearly 65% in the last 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soun-stock-hits-2-month-high-biggest-single-day-gain-price-target-cuts/cZoBcXZRJJE">SOUN Stock Hits 2-Month High, Rallying Toward Biggest Gain in 3 Months Despite Analyst Target Cuts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Doximity, Inc. logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.

DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets

CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.


Doximity Inc

iShares U.S. Healthcare Providers ETF

iShares Core S&P Mid-Cap ETF

Vanguard Health Care ETF

$DOCS

$AAOI

$CRSR

$TEAM

$DOCS, $AAOI, $CRSR, and $TEAM are all surging following their respective earnings reports. Which of these earnings declines are you most interested in buying? Vote and explain your reasoning in the comments.

Which of these earnings rallies are you most interested in buying - $DOCS, $AAOI, $CRSR, or $TEAM?

Current Price	$32.76
Prev Close	$33.63
Open	$33.48
Dividend Yield	0.00%
50-Day Moving Average	$28.29
Beta	1.09
Avg. Volume	2.86M
PE Ratio	38.85

52-Week High	$67.10
52-Week Low	$17.15
Market Capitalization	$5.99B
EPS (Annual)	$0.9849
Price to Book	6.43
Revenue Per Employee	$732,798.86

Feed

News

Sentiment

Earnings

Fundamentals

Info

DOCS Fundamentals